Viking Therapeutics, Inc. (NASDAQ:VKTX) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Viking Therapeutics, Inc. (NASDAQ:VKTX) gained 9.12 Percent and closed its previous trading session at $2.99. The stock traded with the average Volume of 701.63 Million at the end of last session.
Viking Therapeutics, Inc. (NASDAQ:VKTX) has the Market Capitalization of 75.65 Million. The Stock has its 52-week High of $3.80 and 52-Week Low of $0.88 and it touched its 52-week high on 12/06/17 and 52-Week Low on 08/02/17.
The company reported its last earnings Actual EPS of $-0.22/share. While, the analyst predicted that the company could provide an EPS of $-0.2/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.02/share which shows an Earnings Surprise of -10 Percent.
Sell side analysts plays vital role in buying and selling a stock where 3 analysts rated Viking Therapeutics, Inc. (NASDAQ:VKTX) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 9.85% where SMA50 and SMA200 are 22% and 95.91% respectively.
The company shows its Return on Assets (ROA) value of -108.5%. The Return on Equity (ROE) value stands at -202.1%.
Viking Therapeutics, Inc. (NASDAQ:VKTX) currently has a Weekly Volatility of 18.05% percent while its Monthly Volatility is at 13.44% percent. While talking about Performance of the Stock, Viking Therapeutics, Inc. currently has a Weekly performance of 10.74%, monthly performance percentage is 19.12 percent, Quarterly performance is 166.96 percent, 6 months performance shows a percent value of 141.13% and Yearly Performance is 147.11 percent.
Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA JOLLA, United States.